277 related articles for article (PubMed ID: 26138865)
1. Pharmacokinetics and Pharmacodynamics of Twice Daily and Once Daily Regimens of Empagliflozin in Healthy Subjects.
Macha S; Brand T; Meinicke T; Link J; Broedl UC
Clin Ther; 2015 Aug; 37(8):1789-96. PubMed ID: 26138865
[TBL] [Abstract][Full Text] [Related]
2. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.
Friedrich C; Metzmann K; Rose P; Mattheus M; Pinnetti S; Woerle HJ
Clin Ther; 2013 Jan; 35(1):A33-42. PubMed ID: 23328275
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers.
Macha S; Mattheus M; Pinnetti S; Broedl UC; Woerle HJ
Clin Ther; 2015 Jul; 37(7):1503-16. PubMed ID: 26051874
[TBL] [Abstract][Full Text] [Related]
4. Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers.
Macha S; Mattheus M; Pinnetti S; Woerle HJ; Broedl UC
Clin Drug Investig; 2013 May; 33(5):351-7. PubMed ID: 23512637
[TBL] [Abstract][Full Text] [Related]
5. Dapagliflozin twice daily or once daily: effect on pharmacokinetics and urinary glucose excretion in healthy subjects.
Tang W; Reele S; Hamer-Maansson JE; Parikh S; de Bruin TW
Diabetes Obes Metab; 2015 Apr; 17(4):423-5. PubMed ID: 25511685
[TBL] [Abstract][Full Text] [Related]
6. Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers.
Macha S; Sennewald R; Rose P; Schoene K; Pinnetti S; Woerle HJ; Broedl UC
Clin Ther; 2013 Mar; 35(3):226-35. PubMed ID: 23497760
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.
Devineni D; Polidori D; Curtin CR; Murphy J; Wang SS; Stieltjes H; Wajs E
Int J Clin Pharmacol Ther; 2015 Jun; 53(6):438-46. PubMed ID: 25907176
[TBL] [Abstract][Full Text] [Related]
8. Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study.
Heise T; Mattheus M; Woerle HJ; Broedl UC; Macha S
Clin Ther; 2015 Apr; 37(4):793-803. PubMed ID: 25636696
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and multiple-dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus.
Zhao X; Cui Y; Zhao S; Lang B; Broedl UC; Salsali A; Pinnetti S; Macha S
Clin Ther; 2015 Jul; 37(7):1493-502. PubMed ID: 26101175
[TBL] [Abstract][Full Text] [Related]
10. Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes.
Lingvay I; Beetz N; Sennewald R; Schuler-Metz A; Bertulis J; Loley C; Lang B; Lippert C; Lee J; Manning LS; Terada D
Postgrad Med; 2020 May; 132(4):337-345. PubMed ID: 32366156
[TBL] [Abstract][Full Text] [Related]
11. Bioequivalence, Food Effect, and Steady-State Assessment of Dapagliflozin/Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects.
Chang M; Liu X; Cui D; Liang D; LaCreta F; Griffen SC; Lubin S; Quamina-Edghill D; Boulton DW
Clin Ther; 2015 Jul; 37(7):1517-28. PubMed ID: 26048185
[TBL] [Abstract][Full Text] [Related]
12. Relative bioavailability of an empagliflozin 25-mg/linagliptin 5-mg fixed-dose combination tablet
.
Glund S; Mattheus M; Runge F; Rose P; Friedrich C
Int J Clin Pharmacol Ther; 2017 Apr; 55(4):355-367. PubMed ID: 28290274
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes.
Heise T; Seewaldt-Becker E; Macha S; Hantel S; Pinnetti S; Seman L; Woerle HJ
Diabetes Obes Metab; 2013 Jul; 15(7):613-21. PubMed ID: 23356556
[TBL] [Abstract][Full Text] [Related]
14. Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers.
Macha S; Rose P; Mattheus M; Pinnetti S; Woerle HJ
Diabetes Obes Metab; 2013 Apr; 15(4):316-23. PubMed ID: 23094794
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy and safety of arformoterol 15 microg twice daily and arformoterol 30 microg once daily in COPD: a single-dose, multicenter, randomized, modified-blind, two-way crossover study.
Panettieri RA; MacIntyre N; Sims M; Kerwin E; Fogarty C; Noonan M; Claus R; Andrews WT
Clin Ther; 2009 Aug; 31(8):1716-23. PubMed ID: 19808130
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects.
Yang L; Li H; Li H; Bui A; Chang M; Liu X; Kasichayanula S; Griffen SC; Lacreta FP; Boulton DW
Clin Ther; 2013 Aug; 35(8):1211-1222.e2. PubMed ID: 23910664
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers.
Brand T; Macha S; Mattheus M; Pinnetti S; Woerle HJ
Adv Ther; 2012 Oct; 29(10):889-99. PubMed ID: 23054692
[TBL] [Abstract][Full Text] [Related]
18. A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects
.
Dawra VK; Liang Y; Shi H; Bass A; Hickman A; Terra SG; Zhou S; Cutler D; Sahasrabudhe V
Int J Clin Pharmacol Ther; 2019 Apr; 57(4):207-216. PubMed ID: 30802200
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects.
Thompson M; DeJesus E; Richmond G; Wheeler D; Flaherty J; Piliero P; True A; Chiu YY; Zhang Y; McFalls E; Miralles GD; Patel IH
AIDS; 2006 Feb; 20(3):397-404. PubMed ID: 16439873
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers.
Macha S; Dieterich S; Mattheus M; Seman LJ; Broedl UC; Woerle HJ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):132-40. PubMed ID: 23253948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
